Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verweij, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verweij, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:375-376, 1994
© 1994 European Society for Medical Oncology

brief-report

Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer

J. Verweij1,, J. Wanders2, A. L. Nielsen3, N. Pavlidis4, F. Calabresi5, W. ten Bokkel Huinink6, U. Bruntsch7, M. Piccart8, H. Franklin2, S. B. Kaye9 and On behalf of the EORTC Early Clinical Trials Group

1Rotterdam Cancer Institute Rotterdam
2EORTC New Drug Development Office Amsterdam, The Netherlands
3University Hospital of Copenhagen Herlev, Denmark
4University of loannina loannina, Greece
5Instituto Regina Elena Rome, Italy
6Netherlands Cancer Institute Amsterdam, The Netherlands
75 Medizinische Klinik Nurnberg Germany
8Institute Jules Bordet Brussels, Belgium
9Beatson Oncology Centre Western Infirmary, Glasgow, U.K.

Correspondence to: J. Verweij, M.D., Ph.D., Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands

PURPOSE:: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary.

PATIENTS AND METHODS:: Eligibility required histologically proven cancer. Patients with colorectal or non-small cell lung cancer could not have received prior chemotherapy. Patients were entered if WHO PS was ≤2 and organ functions were normal. Treatment consisted of Elsamitrucin 25 mg/m2/week given as a 5–10 min infusion for at least 3–6 weekly doses.

RESULTS:: One hundred and five patients entered the studies, 97 were eligible, 94 are evaluable for toxicity and 75 for response. Toxicity mainly consisted of mild nausea/vomiting, and less frequently reversible hepatotoxicity and malaise. No objective responses were seen.

CONCLUSION:: Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer.

Elsamitrucin, phase II, breast, colorectum, nonsmall cell lung, ovary


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.